{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Secobarbital-Methadone"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K143535",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122904"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIS",
        "DJR"
    ],
    "Summary Letter Date": "December 9, 2014",
    "Summary Letter Received Date": "December 15, 2014",
    "Submission Date": "January 8, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3150",
        "21 CFR 862.3620"
    ],
    "Regulation Name(s)": [
        "Barbiturate test system",
        "Methadone test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Secobarbital",
        "Methadone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Competitive binding",
        "Immunochemistry"
    ],
    "Methodologies": [
        "Immunochromatographic assay",
        "Qualitative rapid test"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Secobarbital-Methadone, a rapid qualitative urine test for secobarbital and methadone by immunochromatographic lateral flow assay",
    "Indications for Use Summary": "Rapid, qualitative detection of secobarbital and methadone in human urine at a cutoff concentration of 300 ng/mL for each drug; for in vitro diagnostic use as a preliminary screening test",
    "fda_folder": "Toxicology"
}